Nephrotic syndrome with impaired GLS (n = 17) | Nephrotic syndrome with normal GLS (n = 23) | P-value | |
---|---|---|---|
Mean ± SD | Mean ± SD | ||
Serum creatinine at the time of assessment (mg/dL) | 0.8 ± 0.05 | 0.79 ± 0.04 | 0.56 |
Serum urea at the time of assessment (mg/dL) | 14 ± 2 | 12 ± 3 | 0.66 |
Serum baseline cholesterol (mg/dL) | 226 ± 12 | 232 ± 10 | 0.56 |
Serum cholesterol at the time of assessment (mg/dL) | 177 ± 21 | 173 ± 20 | 0.72 |
Serum baseline albumin (gm/dL) | 2.2 ± 0.1 | 2.3 ± 0.2 | 0.56 |
Serum albumin at the time of assessement (gm/dL) | 2.4 ± 0.3 | 2.9 ± 0.1 | < 0.001 |
Baseline urine P/C ratio | 6 ± 0.9 | 5 ± 1 | 0.65 |
Urine P/C ratio at the time of assessment | 3 ± 0.7 | 1.4 ± 0.4 | < 0.001 |
Duration from onset of NS to time of assessment by echocardiography (weeks) | 16 ± 1 | 14 ± 2 | 0.39 |
Duration of steroid therapy (weeks) | 14.8 ± 2 | 15.9 ± 3 | 0.5 |
Dose of steroid (mg/kg/day) | 2 ± 0 | 2 ± 0 | 0.9 |
Weight difference from the onset to time of assessment (kg) | 2.2 ± 0.2 | 3.1 ± 0.3 | < 0.001 |
3D LVEDV (ml) | 61 ± 12 | 58 ± 22 | 0.45 |
3D EF (%) | 77 ± 3.2 | 79 ± 4 | 0.40 |
FS (%) | 46 ± 2 | 46 ± 3 | 0.23 |
GLS (%) | 14 ± 3.2 | 18 ± 1.41 | < 0.0001 |
E/e′ | 12 ± 2 | 8 ± 1.29 | < 0.0001 |